Hyderabad: Czech HealthTech company Kardi Ai launched its AI-powered long-term cardiac monitoring technology in India on Saturday. The Kardi Ai ECG monitoring system combined a wearable device, mobile connectivity and AI-supported analysis to track heart rhythms over longer periods.
Dr Balakrishna, Joint Director, Ministry of Electronics and Information Technology, Government of India, formally launched the technology at Daspalla Hotel in Jubilee Hills.
Kardi Ai co-founder and CEO Vlastimil Hrabal attended the event. Kardi Ai India representative Dr Ramana Jagarlamudi and Eurasia Medical Technologies co-founder Dr Raghavendra Rao also participated.
CzechTrade official Josef Hrubec and film director Krish Jagarlamudi attended alongside cardiologists, doctors and other healthcare professionals.
Kardi Ai ECG monitoring extends observation period
Addressing more than 200 participants, Hrabal said the company developed the technology to simplify long-term ECG monitoring. “At Kardi Ai, we are pioneers in the digital transformation of healthcare,” he said. He added that AI could make long-term monitoring more affordable and easier to integrate into daily life.
Hrabal said heart rhythm abnormalities could occur unpredictably. As a result, they might not appear during a short ECG test or conventional 24-hour Holter recording.
He said a standard ECG provided a brief snapshot of heart activity. A Holter monitor, meanwhile, usually recorded activity for a limited period.
Kardi Ai ECG monitoring was designed to extend that observation period. Hrabal said longer monitoring could give doctors more opportunities to identify intermittent abnormalities.
He said Hyderabad had about 700 cardiologists, compared with around 1,000 in the Czech Republic. He also said the technology could support efforts to prevent serious cardiac events.
Wearable device sends ECG data through mobile platform
Patients using the technology wear a lightweight ECG chest strap during normal daily activities. The system transmits recorded data through its mobile platform.
AI-supported analysis then assists doctors in reviewing ECG recordings and identifying potential rhythm abnormalities. The company said longer monitoring could help identify intermittent arrhythmias that shorter tests might miss.
Kardi Ai reported detection rates of up to 40 per cent with its technology. It compared this with approximately 2 to 5 per cent for conventional Holter monitoring. However, the company said detection rates could vary with patient populations, monitoring protocols and clinical definitions.
The technology supported physicians and did not replace clinical diagnosis or medical decisions. According to company guidance, the application provided only preliminary AI-supported analysis. A physician must make the final diagnosis after appropriate clinical evaluation, the company said.
Company cites medical device approvals
Kardi Ai introduced the product in India as prescription-grade medical technology rather than a consumer fitness device. The company said it had obtained an MD-15 licence from the Government of India for import and sale. It also said the product carried CE marking under the European Union medical device framework.
According to Kardi Ai, regulators classified the technology as an EU MDR Class IIa medical device. The company also said its quality and manufacturing processes aligned with the ISO 13485 medical device standard.
Josef Hrubec, CzechTrade India-Bengaluru Director, also addressed the launch. He said more than 37 Czech companies operated in India, with investments exceeding US$283 million. Their activities included automotive, engineering and infrastructure sectors, he added.
“Kardi Ai is an interesting new-generation Czech company,” Hrubec said. He said its entry reflected growing Czech activity in HealthTech, AI and digital healthcare. CzechTrade is a Czech government agency that promotes trade and cooperation between Czech and foreign businesses.
Indian partner explores future manufacturing
Hyderabad-based Eurasia Medical Technologies LLP facilitated the India launch as Kardi Ai’s authorised representative. Dr Ramana Jagarlamudi and Dr Raghavendra Rao said healthcare was increasingly moving towards remote monitoring and digital health. They also cited growing use of AI-assisted clinical decision support.
The Indian partners said they were exploring the possibility of manufacturing the technology in India in the future. The launch also included discussions involving doctors and technology stakeholders. Topics covered cardiac arrhythmias, remote cardiac care and long-term ECG monitoring.
Participants also discussed the potential role of AI-supported ECG analysis in clinical practice. The company launched the technology under the theme “From Signal to Insight for Healthier Lives.”